Aim: Renal venous hypertension is known to be associated with worsening of renal function in patients with decompensated heart failure. Intra-abdominal hypertension including cirrhotic ascites also leads to renal venous hypertension. We aimed to clarify the effect of renal venous hypertension on cirrhotic ascites.
INTRODUCTION

L
IVER CIRRHOSIS HAS numerous severe sequelae, including jaundice, hepatic coma, and ascites. Cirrhotic ascites is associated with a reduced patient quality of life and an increased frequency and duration of hospital admissions. 1 The development of cirrhotic ascites is associated with a 5-year survival rate of approximately 50% without liver transplantation. 2 Moreover, various complications, such as hyponatremia, 3 spontaneous bacterial infection, 4 and hepatorenal syndrome, 5 which are associated with a poor prognosis, may occur in patients with cirrhotic ascites. To date, the predictors of cirrhotic ascites prognosis have been analyzed in numerous studies. 3, [6] [7] [8] Although the Child-Pugh score has shown utility in predicting liver cirrhosis outcomes, it is not a valuable tool in the setting of severe uncompensated cirrhosis. 6 The Model for Endstage Liver Disease (MELD) score has greater utility in cases of severe liver cirrhosis. 9 Furthermore, hyponatremia has been recognized as a prognostic factor for liver cirrhosis. 7 The MELD score combined with serum sodium levels (MELD-Na) is reportedly more accurate for predicting survival in such cases. 7 The association between venous hypertension and chronic heart failure was first recognized in 1950. 10 Renal dysfunction in the setting of heart failure may be because of renal venous hypertension in addition to decreased cardiac output. This phenomenon has been termed the cardiorenal syndrome. 11 Renal venous hypertension is thought to result in renal dysfunction through various mechanisms, including a decreased transglomerular pressure gradient, increased renal intestinal pressure, and vasoconstriction. 12 Furthermore, intra-abdominal hypertension results in renal venous hypertension. 13 Decompensated liver cirrhosis is one of the major causes of massive ascites. However, the association between cirrhotic ascites and renal venous hypertension remains unknown.
Although several markers have been assessed for the evaluation of renal venous hypertension, none have shown sufficient utility for general use. The measurement of central venous pressure (CVP) requires an invasive procedure, 14, 15 and the size of the inferior vena cava (IVC) may vary according to the respiratory status or measurement site.
We aimed to clarify the effect of renal venous hypertension on cirrhotic ascites.
METHODS
Patients
T HIS OBSERVATIONAL STUDY
comprised 142 consecutive patients who were admitted for cirrhotic ascites from December 2008 to July 2016 at the Nihon University School of Medicine (n = 132; Tokyo, Japan) and the Japan Community Health Care Organization Yokohama Chuo Hospital (n = 10; Chiba City, Japan). The inclusion criteria were as follows: (i) patients admitted for cirrhotic ascites, which was refractory to 40 mg furosemide and 50 mg oral spironolactone; (ii) patients with a first admission for cirrhotic ascites; (iii) patients who underwent computed tomography (CT) in the time period between 30 days before and 7 days after hospital admission; and (iv) patients aged >20 years. We excluded patients with: (i) hepatocellular carcinoma stages B, C, or D of the Barcelona Clinic Liver Cancer staging classification; 16 (ii) malignancy of other organs; (iii) receiving maintenance dialysis; (iv) a history of nephrectomy; (v) the nutcracker phenomenon; (vi) right-sided heart failure; or (vii) severe thrombosis.
The diagnosis of cirrhosis was based on a compatible a history of chronic liver disease, physical examination findings, laboratory testing, and the presence of signs of cirrhosis and/or portal hypertension (nodular liver, splenomegaly, gastroesophageal varices, and other collaterals) on imaging studies including CT, ultrasonography, and gastrointestinal endoscopy. All patients underwent paracentesis to rule out other causes of ascites, such as peritoneal carcinomatosis and abdominal infections (except for spontaneous bacterial peritonitis). Congestive heart failure was ruled out because of the absence of cardiomegaly in CT findings. The patients had a mean follow-up duration of 5.2 ± 16.0 months.
This retrospective study was carried out according to the principles of the Declaration of Helsinki. Clinical data, including serological and follow-up data, were obtained from the hospital records for all cases. This study was approved by Nihon University Institutional Review Board, and the necessity of informed consent was waived because of the retrospective study design.
Clinical assessments and blood tests
Clinical assessments and routine blood examinations, including tests for hemoglobin, platelet count, total bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, serum albumin, creatinine, blood urea nitrogen, sodium, and prothrombin time-international normalized ratio (PT-INR), were carried out on admission.
Protocol for CT
Computed tomography scans were carried out using a multidetector row 4-, 16-, 64-, or 320-slice raw scanner (Light-Speed, GE Healthcare, Piscataway, NJ, USA; Somatom, Siemens Healthcare, Germany; or Aquilion ONE, Toshiba Medical Systems, Tokyo, Japan), with a collimation of 2.5-5 mm, section thickness of 3-5 mm, and reconstruction of 2.5-3 mm, using a triphasic liver protocol in a decubitus position, under fasting conditions. Scanning was undertaken using a 15.0-or 53.0-helical pitch, table feed speed of 0.75 or 0.5 mm per rotation, and voltage of 120 kV. For the triphasic protocol, images were obtained at 30-35, 60-70, and 180-300 s after the initial i.v. injection of 120 mL ioversol (Optiray 240; Mallinckrodt, St. Louis, MO, USA), iohexol (Omnipaque 350; Nycomed Amersham, Piscataway, NJ, USA), or iodixanol (Visipaque; GE Healthcare, Princeton, NJ, USA) at a rate of 5 mL/s. The contrast medium was injected using a power injector (Dual-Shot; Nemoto-Kyorindo, Tokyo, Japan).
Patients underwent CT in a fasting state, and treatments, including paracentesis, were subsequently started.
Measurement of renal vein, portal vein, and IVC using non-contrast CT The renal vein diameter was measured at the main trunk of the renal vein, downstream of the confluence of branches and upstream of the confluence of collateral veins. The left renal vein was measured (except for Fig. 1 ) because multiple renal veins were more frequently observed in the right side than the left side. 17 The major and minor axes of the IVC were measured downstream of the bilateral renal The renal vein, portal vein, and IVC were independently measured by two hepatologists (N.M. and M.H.), with 16 and 8 years of imaging experience, respectively. Evaluators were blinded to patient clinical data. The median values of both measurements were used in further analyses. Measurements were carried out using non-contrast CT for the renal vein in all patients and for the portal vein and IVC in 87 patients. The portal phase of contrast-enhanced CT (CECT) was used for comparison with non-contrast CT images in 37 patients.
Statistical analyses
The data are expressed as mean ± standard deviation. Patient characteristics were compared using the MannWhitney U-test and χ 2 -test. Probability curves were obtained using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate analyses were carried out using a Cox proportional hazards model for evaluating patient survival. The exploratory correlations were assessed using Pearson's correlation coefficient with 95% confidence intervals (CI). The diagnostic value of the index was assessed by calculating the area under the receiver operating characteristic (AUROC) curves. P-values <0.05 were considered statistically significant for all analyses. All statistical analyses were undertaken using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, EZR is a modified version of R Commander, which is designed to add statistical functions that are frequently used in biostatistics. 18 
RESULTS
Patient characteristics
O F 201 IDENTIFIED patients, 59 patients were excluded because of advanced hepatocellular carcinoma (n = 54), history of nephrectomy (n = 2), receipt of maintenance dialysis (n = 2), and malignancy of other organs (n = 1); 142 patients met the inclusion criteria. Patient demographic data, clinical characteristics, and laboratory data are summarized in Table 1 . All patients had decompensated liver cirrhosis. Patients comprised 95 men and 47 women (median age, 69 years; range, 43-86 years); 68 patients (47.9%) were in Child-Pugh class B, and 74 patients (52.1%) were in Child-Pugh class C. The causes of cirrhosis included hepatitis C (n = 45), alcohol consumption (n = 51), hepatitis B (n = 8), hepatitis C with alcohol consumption (n = 9), and others (n = 29). Albumin infusion was used in all cases. In addition, tolvaptan (n = 55), paracentesis (n = 54), cell-free and concentrated ascites reinfusion therapy (n = 5), 19 and peritoneal venous shunting (n = 1) were administered for ascites. The types and doses of diuretics were as follows: furosemide (10 mg, n = 4; 20 mg, n = 60; 40 mg, n = 39; 60 mg, n = 12; 80 mg, n = 7; 100 mg, n = 1), spironolactone (25 mg, n = 4; 50 mg, n = 20), and canrenoic acid (200 mg, n = 50; 400 mg, n = 19; 600 mg, n = 2). 
Inter-observer agreement
Inter-observer agreement was high for measurements of the left renal vein (r = 0.918, P < 0.001; Fig. 2 ), IVC area (r = 0.957, P < 0.001), and portal vein (r = 0.869, P < 0.001).
Correlation between non-contrast and contrast-enhanced CT Contrast-enhanced CT was undertaken in 37 patients. The right and left renal vein diameters determined using non-contrast CT were correlated with those determined using CECT (r = 0.79 and 0.939, respectively; both P < 0.001; Fig. 3 ).
Prognostic significance of renal vein, IVC, and portal vein dilation
During the observation period, 64 patients died and no patient received transplantations. The causes of death were liver failure (n = 46), gastrointestinal hemorrhage (n = 2), hepatocellular carcinoma (n = 1), sepsis (n = 1), spontaneous bacterial peritonitis (n = 1), cardiac failure (n = 1), aspiration pneumonitis (n = 1), and cerebral hemorrhage (n = 1). The median overall survival (OS) for patients with a left renal vein diameter ≥ 11 mm was less than that for patients with renal vein diameter <11 mm (P < 0.001; 2.5 vs. 32.0 months; Fig. 4a) , and the 1-year survival rates were 15.3% and 66.4%, respectively. When patients were divided into three groups according to their left renal vein diameter (<7.5 mm, 7.5-12.5 mm, and >12.5 mm), the median OS was 32.0, 19.5, and 1.9 months, respectively (P = 0.004; Fig. 4b ), and the 1-year survival rates were 73.9%, 54.2%, and 27.6%, respectively. The median OS for patients with a large IVC was less than that for patients with a small IVC (P = 0.038; 3.4 vs. 32.0 months).
Differences in patient characteristics between renal vein dilation and non-dilation groups
Patient comparison based on the left renal vein diameter indicated that patients with a renal vein diameter-11 mm were younger (P = 0.027), had a higher MELD score (P = 0.003), had a higher MELD-Na score (P < 0.001), were more likely to be in Child-Pugh class C (P = 0.014), had higher serum total bilirubin levels (P < 0.001), had higher serum direct bilirubin levels (P < 0.001), had a higher PT-INR (P < 0.001), and had lower serum sodium levels (P = 0.008; Table 1 ). The correlation coefficients between the left renal vein diameter and total bilirubin, direct bilirubin, PT-INR, and serum albumin were 0.304 (P < 0.001), 0.370 (P < 0.001), 0.258 (P = 0.003), and À0.057 (P = 0.506).
Predictive factors of mortality in patients with refractory cirrhotic ascites
Univariate analysis for mortality included the MELD-Na score, Child-Pugh class, IVC area, portal vein diameter, and left renal vein diameter. Multivariate analysis revealed that a high MELD-Na score (hazard ratio [HR], 3.388; P < 0.001; 95% CI, 2.001-5.737) and renal vein diameter >11 mm (HR, 2.944; P < 0.001; 95% CI, 1.666-5.203) were significant independent predictors of mortality. When MELD-Na was divided into each component, renal vein diameter >11 mm was also independent predictor of mortality (Table 2) .
Diagnostic accuracy of 6-month survival rate using MELD-Na scores and renal vein diameter
The AUROC for 6-month survival was 0.762, using the MELD-Na score. The MELD scores were assigned as follows: left renal vein diameter <7.5 mm = 0 points, 7.5-12.5 mm = 1 point, and >12.5 mm = 2 points. In addition to this score, when MELD-Na was considered, the AUROC for 6-month survival improved from 0.762 to 0.778 (P = 0.076; Fig. 5 ).
DISCUSSION
I
N THE PRESENT study, renal vein dilation determined using CT was correlated with poor outcomes in patients with refractory cirrhotic ascites. To the best of our knowledge, this is the first report describing a relationship between renal vein dilation and the outcome of patients with cirrhotic ascites.
The prognostic factors for decompensated liver cirrhosis have been evaluated in numerous studies. 
Although the Child-Pugh score classifies patients with liver cirrhosis according to their prognosis, 6 this classification cannot precisely predict mortality in patients with chronic liver failure. 8 The MELD score was developed to evaluate patients who were candidates for liver transplantation 9 and has been widely used to predict the outcomes of decompensated liver cirrhosis. Hyponatremia is strongly correlated with mortality from liver cirrhosis. 3 The MELD-Na score is reportedly more accurate for predicting survival. 7 The present study compared renal vein dilation with the MELD-Na score for predicting mortality from cirrhosis. However, the effect of renal venous hypertension on the development and progression of liver cirrhosis remains unknown.
Experimental swine studies have reported intraabdominal pressure to be correlated with renal venous pressure. 13, 20 Furthermore, renal venous pressure increases as ascites increases in patients with liver cirrhosis. 13 Moreover, studies have revealed that IVC compression by the liver in the supine position results in increased IVC pressure. 21 Thus, in the setting of decompensated liver cirrhosis, renal venous hypertension may arise from IVC compression by the liver and from abdominal ascites. We consider that the renal vein diameter is likely correlated with renal venous pressure because the IVC diameter has been positively correlated with CVP in previous studies. 22 We consider renal vein dilation as an equivalent of renal venous hypertension. The results of the present study indicate that renal venous hypertension is associated with poorer outcomes in patients with cirrhotic ascites.
Renal venous hypertension has long been studied by cardiologists and is known to be associated with cardiac function. 10 Previous published work has shown that high CVP is correlated with the prevalence of renal dysfunction in patients with decompensated heart failure.
14 Rightsided heart failure causes renal dysfunction through renal venous hypertension. 15 Various mechanisms of renal impairment have been proposed, 12 including a decreased transglomerular pressure gradient, 23 increased renal interstitial pressure, 24 renal arterial vasculature myogenic responses, 25 neural vasoconstrictive reflexes, 26 renin-angiotensin-aldosterone system activation, 24, 27, 28 endothelin release, 29 and reactive oxygen species release. 29, 30 A recent study reported that the monophasic pattern of intrarenal venous waveforms measured using color Doppler ultrasonography is correlated with high mean right atrial pressure and poor prognosis. 31 However, studies are yet to describe the relationship between renal vein diameter and prognosis. We consider cirrhotic ascites to be similar to right-sided heart failure in terms of venous congestion.
Renal vein diameter was measured using non-contrast CT in the present study because most of the included patients had renal dysfunction. Previous studies have evaluated congenital renal vein anomalies using CECT. 32 We consider non-contrast CT as an appropriate alternative to CECT because a correlation was observed between renal vein diameter measurements by both non-contrast CT and CECT (Fig. 3) . Magnetic resonance venography has been used for the evaluation of renal vein diameter; 33 however, it is considered unsuitable in patients with massive ascites because of excessive pain during the long examination period. Color Doppler ultrasonography is a less invasive method that can measure both renal vein diameter and flow velocity. Blood flow volume may be calculated from vessel diameter and flow velocity. 34 Although the measurement of renal artery blood flow using Doppler ultrasonography has been used in clinical settings for several years, 35 techniques for the measurement of renal vein diameter need to be established.
In this study, significant differences were observed between renal vein dilation and non-dilation groups. Worse Figure 5 Area under the receiver operating characteristic curve (AUROC) for 6-month survival was 0.762 with Model for Endstage Liver Disease and serum sodium level (MELD-Na) score in patients with refractory cirrhotic ascites. When scores were assigned as follows: left renal vein diameter <7.5 mg = 0 point, 7.5-12.5 mg = 1 point, and >12.5 mg = 2 point, in addition to this score and MELD-Na, the AUROC for 6-month survival improved from 0.762 to 0.778 (P = 0.076).
MELD and MELD-Na scores and Child-Pugh class were more frequent in patients with renal vein dilation because of higher bilirubin levels and higher PT-INR. Few surrogate markers of renal venous hypertension have been proposed by previous studies. 14, 15, [36] [37] [38] Central venous pressure was first reported with regard to renal dysfunction and can be used as a direct measure of venous hypertension. 14, 15 Hyperbilirubinemia has been reported as a predictive factor of acute heart failure, 36 decompensated heart failure, 37 and pulmonary hypertension. 38 Serum total bilirubin has been shown to be correlated with CVP and pulmonary artery wedge pressure.
37 Therefore, we consider bilirubin level correlated with renal vein diameter and CVP.
Renal vein diameter is not influenced by renal function because serum blood urea nitrogen level, creatinine level, and urine osmolality showed no difference between the two groups in this study. Although diuretics have adverse effects on renal function, the type and dose of diuretics also did not relate to renal vein diameter. Patients with chronic renal failure have small kidney in size and blood flow volume, so we excluded patients who received maintenance dialysis in this study.
The present study has several limitations that need to be considered when interpreting the results. First, the sample size of 142 patients is relatively small and includes only patients of Japanese ethnicity. However, this sample size is larger than that of prior studies on cirrhotic ascites with renal venous hypertension. 13 Second, CT is unable to evaluate blood flow velocity or blood pressure. Although we measured renal vein diameter in the present study, further study using color Doppler ultrasonography or magnetic resonance imaging is required to assess renal venous blood flow. Third, the correlation between renal venous hypertension and renal vein diameter is not proven. The measurement of renal venous pressure using a catheter in patients with massive ascites is difficult, because it is an invasive procedure, and these patients find it painful to maintain a supine position. Finally, it is difficult to exclude conditions that cause IVC obstruction such as BuddChiari syndrome and thrombosis. Abdominal ultrasonography was carried out in most cases, which showed the absence of IVC and hepatic vein occlusion.
In conclusion, the results of the present study suggest that renal vein dilation, determined using non-contrast CT, is an independent predictor of mortality in the setting of massive cirrhotic ascites, regardless of the MELD-Na score. The mechanism of renal venous hypertension is considered as IVC compression by the liver and ascitic fluid. Studies using other imaging techniques are required to validate the findings of this cross-sectional study.
